StreetAlpha
13F holdings · Q3 2026

Baker Bros. Advisors

New York, NY · files as Baker Bros. Advisors LP
Know the moment Baker Bros. Advisors filesYou follow Baker Bros. Advisors An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1263508

Baker Bros. Advisors reported 79 stocks worth $21B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are INCY (17.8%), ONC (15.4%) and RVMD (10.4%). Compared with Q2 2026, the fund opened new positions in TRAX, SCTX and FRNM, added to ONC, KOD and CLDX, trimmed RVMD, CELC and ROIV and sold out of ALMS, VRDN and SION.

Latest filing: what Baker Bros. Advisors did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
5 new7 added11 trimmed9 sold outBought about $305M · sold about $958M
New 5
Added 7
See all 7 →
Trimmed 11
See all 11 →
Sold out 9
See all 9 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$21B+5.5% vs last quarter
Stocks held795 new · 9 sold out
Top 5 weight58.6%fairly concentrated
Turnover6%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
INCY
Incyte Corp
$3.7B17.8%30.8MNo change8 of 8
2
ONC
Beone Medicines Ltd
$3.2B15.4%8.8M+31K (+0%)8 of 8
3
RVMD
Revolution Medicines Inc
$2.2B10.4%10.6M−806K (−7%)8 of 8
4
KOD
Kodiak Sciences Inc
$2.1B9.9%21.9M+1.9M (+10%)8 of 8
5
MDGL
Madrigal Pharmaceuticals Inc
$1.1B5.2%2.1MNo change8 of 8
6
INSM
Insmed Inc
$1B4.8%8.8MNo change8 of 8
7
KYMR
Kymera Therapeutics Inc
$968M4.6%8.7MNo change8 of 8
8
ACAD
Acadia Pharmaceuticals Inc
$865M4.1%42.9MNo change8 of 8
9
GRAL
Grail Inc
$564M2.7%4MNo change8 of 8
10
SMMT
Summit Therapeutics Inc
$554M2.6%32.8MNo change8 of 8
🔒 69 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
CRINETICS PHARMACEUTICALS IN
$88M2.4M
ALMS
Alumis Inc
$56.6M2M
VRDN
Viridian Therapeutics Inc
$43.8M2.4M
SION
Sionna Therapeutics Inc
$17.6M400K
VSTM
Verastem Inc
$9.5M2.5M

🔒 Free account: see all 9.

Reported value

last 8 quarters
$9.2BQ4 '24
$8.9BQ1 '25
$10.3BQ2 '25
$13.8BQ3 '25
$17BQ4 '25
$17.4BQ1 '26
$19.9BQ2 '26
$21BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Baker Bros. Advisors 13F FAQ

What does Baker Bros. Advisors own?

Baker Bros. Advisors reported 79 stocks worth $21B in its 13F filing for Q3 2026, filed Nov 16, 2026. The table above lists every position in the filing (the top 10 without an account).

What did Baker Bros. Advisors buy and sell in Q3 2026?

Compared with Q2 2026: 5 new positions, 7 added to, 11 trimmed and 9 sold out. New positions include TRAX, SCTX and FRNM. It sold all of ALMS, VRDN and SION.

When will Baker Bros. Advisors file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Baker Bros. Advisors's portfolio worth?

The Q3 2026 filing reports $21B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.